Endocardial Solutions To Ship EnSite 3000 For Right Atrial Mapping In May
This article was originally published in The Gray Sheet
Executive Summary
Shipments of Endocardial Solutions, Inc.' s EnSite 3000 system are anticipated to begin in early May following 510(k) clearance April 21 for use in diagnostic mapping of complex arrhythmias in the right atrium of the heart.
You may also be interested in...
Endocardial Solutions
Private placement of 1.1 mil. shares of common stock to institutional investors raises $10 mil. Proceeds will be used to help finance market introduction of the firm's $175,000 Ensite 3000 system, which was cleared by FDA for mapping of right atrial arrhythmias on April 21 and launched in early May (1"The Gray Sheet" April 26, p. 10). The firm has expanded its marketing force from ten to twenty reps since the launch and has a PMA pending at FDA for left atrial indications. Second-quarter financial results announced July 21 include revenues of $1.7 mil., compared to $435,406 for the second quarter of 1998. A net loss of $3.8 mil. compares to losses of $3.3 mil. for the comparable quarter last year
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.